Authors

  • Parpibayeva D.A., Buvamuxamedova N.T.

Keywords:

surunkali yurak yetishmovchiligi, metabolik assotsirlangan jigar yog‘ kasalligi, jigar fibrozi, erta diagnostika, NT-proBNP, sitokeratin-18, PRO-C3, noinvaziv biomarkerlar, komorbidlik.

References

1. Ballestri S., Mantovani A., Baldelli E., et al. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics. 2021;11:98.

2. Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population. Journal of the American Heart Association. 2023.

3. The Liver in Heart Failure: From Biomar-kers to Clinical Risk. PMC (MDPI, Nutrients). 2023.

4. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. Nutrients. 2023;15:3970.

5. Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (PNPLA3 and TM6SF2), is associated with hospitalization or death from heart failure: a prospective UK Biobank study. medRxiv. 2023.

6. Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with MAFLD. PMC.

7. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLOS One. 2020.

8. Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis. PMC.

9. Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage. PMC. 2023.

10. AVIATION Study: Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Non-Cirrhotic NASH. ClinicalTrials.gov SAP.

11. Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis. PMC. 2024.

12. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PubMed. 2020.

13. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and MMP-2 Levels in Chronic Hepatitis B Patients with Cirrhosis. PMC.

14. Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy. PMC. 2024.

15. Karsdal M.A., et al. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology. 2018;53(1).

16. Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure. PMC. 2019.

17. Utility of collagen-derived peptides as markers of organ injury in patients with acute heart failure. PMC. 2020.

18. Plasma levels of PRO-C3, a type III collagen synthesis marker, are associated with arterial stiffness and increased risk of cardiovascular death. Atherosclerosis. 2023.

19. Extracellular Matrix in Heart Disease: Focus on Circulating Collagen Type I and III Derived Peptides as Biomarkers of Myocardial Fibrosis in Heart Failure. PMC. 2022.

20. Procollagen C-Proteinase Enhancer 1 (PCPE-1) is a marker of myocardial fibrosis and impaired cardiac function in a murine model of pressure overload. bioRxiv.

21. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLOS One. 2015.

22. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. PMC. 2020.

23. Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients. PMC. 2023.

24. Non-alcoholic fatty liver disease as an emerging risk factor for heart failure. PMC. 2023.

25. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. JACC. 2022.

26. The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. PMC.

27. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. PubMed. 2018.

28. NAFLD Linked With Increased Heart Failure Risk (meta-analysis summary, 11 million patients). Medscape. 2022.